Selecta Biosciences, Inc. has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH), for the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention. The grant will support the funding of a clinical drug candidate from Selecta’s pipeline, and assist with advancing a nicotine vaccine through early clinical development. The award is provided ...